This drop brings the stock's year-to-date decline to almost 45%. A key question now is how MRNA's performance compares to that of its competitors.

Moderna, Inc. remains under pressure in 2025, despite recent next-gen COVID vaccine approval & cancer vaccine trial. Learn ...

Moderna (MRNA), with its widely used COVID-19 vaccine, rose to prominence during the global pandemic. The stock soared an eye ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped in the afternoon session after the company presented promising early data for its investigational cancer antigen therapy, ...

In the latest close session, Moderna (MRNA) was up +1.87% at $26.74. The stock outpaced the S&P 500's daily gain of 0.79%. Elsewhere, the Dow saw an upswing of 1.01%, while the tech-heavy Nasdaq ...

The vaccine, known as mRNA-1647, showed disappointing efficacy against primary CMV infection in healthy women, ranging from just 6% to 23% depending on the case definition used. As a result, Moderna ...

Moderna Inc. (NASDAQ:MRNA) is one of the best high volume stocks to buy according to Wall Street analysts. On October 13, ...

In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis (CF). | In a mixed interim data drop, Arcturus ...

Moderna (MRNA) has drawn attention after its stock climbed around 12% over the past week. Investors are weighing the company’s recent financial results, as annual revenue shows about 20% growth and ...

Shares of Moderna MRNA were up 4% yesterday after the company announced positive preliminary immunogenicity data from an ongoing phase IV study, which evaluated the updated version of its COVID-19 ...

After entering into a definitive agreement to acquire CureVac—who focuses on mRNA-based medicines for oncology and infectious ...